Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Exion Labs Inc. currently manages a patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The prosecution activity includes 1 pending office action. This 1 pending office action represents the current interaction with the patent office in this sector. For a company in this technology area, maintaining a path through the examination process is a component of protecting its biological and pharmaceutical innovations. The Biotechnology & Pharmaceuticals field requires rigorous technical support during prosecution.
The examination of these assets is handled by 1 distinct examiner working within 1 distinct art unit. This indicates a concentrated channel of review for the portfolio, where the perspective of 1 individual governs the immediate outcomes of the pending matters. The presence of 1 distinct art unit suggests the subject matter is clustered within a specific technical niche. This structure means the applicant does not have to navigate different sets of examination guidelines across multiple units for the 1 distinct examiner involved.
WHEELER, THURMAN MICHAEL is the busiest examiner for this portfolio, currently overseeing 1 busiest examiner pending office action. Because this examiner is responsible for the pending action, the prosecution strategy for Exion Labs Inc. is tied to the requirements of this official. This concentration simplifies the monitoring process but makes the decision-making of 1 distinct examiner central to the overall portfolio status. Practitioners can focus on the preferences of WHEELER, THURMAN MICHAEL to address the pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHEELER, THURMAN MICHAEL | 1 | 45.8% | +23.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17869477 | POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | WHEELER, THURMAN MICHAEL | 86d |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17869477 | POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | WHEELER, THURMAN MICHAEL | 1619 | §103DP | Final Rejection | 86d | Pending | Jul 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial